Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 6/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | PRKACG | P22612 | 1/20 | 0.48 |
| ▸ | PRKACB | P22694 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 4/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | PRKCB | P05771 | 4/20 | 0.39 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905932 | 0.90 | GAA (0.52) | PRKCAPIM1PRKACAPRKACGPRKACB | |
| SCHEMBL2902498 | 0.86 | KAT2B (0.43) | PRKCAPIM1PRKACAPRKACGPRKACB | |
| SCHEMBL2904324 | 0.85 | GAA (0.48) | PRKCAGSK3BCCNE2CDK4CCND1 | |
| SCHEMBL2907165 | 0.84 | GSK3B (0.47) | PRKCAGSK3BPRKCBPRKCEALDH1A1 | |
| SCHEMBL2902665 | 0.78 | GAA (0.49) | PRKCAGSK3BPRKCBALDH1A1HSD17B10 | |
| SCHEMBL2901717 | 0.77 | GAA (0.48) | PRKCAGSK3BALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL2904983 | 0.77 | RAD52 (0.48) | PRKCAPRKACAPRKACGPRKACBPRKCB | |
| SCHEMBL2901598 | 0.77 | GAA (0.48) | PRKCAPIM1PRKACAGSK3BCDK2 | |
| SCHEMBL2904581 | 0.76 | GAA (0.47) | PIM1PRKACAGSK3BKMT2ANQO2 | |
| SCHEMBL2904842 | 0.75 | GAA (0.48) | PRKCAPIM1GSK3BALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874761-B1 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | claimed |
| EP-1874761-B1 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | disclosed |
| EP-1874761-B1 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | disclosed |
| US-7517881-B2 | Triazine derivatives, their preparation and therapeutic application thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-7517881-B2 | Triazine derivatives, their preparation and therapeutic application thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-7517881-B2 | Triazine derivatives, their preparation and therapeutic application thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-04-24 | — | — | US | disclosed |
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-04-24 | — | — | US | disclosed |
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-04-24 | — | — | US | disclosed |
| EP-1874761-A2 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | Aventis Pharma S.A. (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111662-A2 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | AVENTIS PHARMA S.A. (FR) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | CYP11B2, IL5, TBXA2R | PRKCA 4781/4885PIM1 2578/4885PRKACA 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.